Glenmark Pharma gains after American subsidiary launches Olopatadine generic

Glenmark Pharmaceuticals added 1.53% to Rs 1588.65 after the company's subsidiary Glenmark Therapeutics Inc., USA, announced the launch of OTC product Olopatadine Hydrochloride Ophthalmic Solution.